Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Heart Transplantation

Interventions

BIOLOGICAL

Autologous thyTreg

Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)

Trial Locations (1)

RECRUITING

Hospital General Universitario Gregorio Marañon, Madrid

All Listed Sponsors

collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Rafael Correa-Rocha

OTHER